>サウジアラビア、トルコ、エジプトの HbA1c 検査市場、製品タイプ別 (機器、試薬、消耗品)、検査モード別 (処方箋に基づく検査と OTC 検査)、技術別 (イオン交換 HPCL、酵素アッセイ、アフィニティー結合クロマトグラフィー、比濁阻害免疫測定法など)、エンドユーザー別 (研究所、病院、診療所、在宅ケア、外来センター、薬局/ドラッグストアなど)、流通チャネル別 (サードパーティ流通、直接販売、小売販売) – 2030 年までの業界動向と予測。
サウジアラビア、トルコ、エジプトの HbA1c 検査市場の分析と洞察
糖尿病と腎臓疾患に関する意識の高まりにより、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げと承認に注力しています。さらに、糖尿病用の改善されたポイントオブケアデバイスの増加も、糖尿病またはHBA1C検査の需要の増加に貢献しています。
データブリッジマーケットリサーチは、HbA1c検査市場は2023年から2030年の予測期間に4.4%のCAGRで成長すると予想され、サウジアラビアでは2030年までに6,159万米ドルに達すると予想され、トルコでは2023年から2030年の予測期間に5.4%のCAGRで成長すると予想され、トルコでは2030年までに7,373万米ドルに達すると予想され、エジプトでは2023年から2030年の予測期間に5.4%のCAGRで成長すると予想され、エジプトでは2030年までに6,594万米ドルに達すると予想されていると分析しています。機器セグメントは、高度な技術の開発により市場の成長を促進すると予測されています。
レポートメトリック |
詳細 |
予測期間 |
2023年から2030年 |
基準年 |
2022 |
歴史的な年 |
2021 (2015~2020年にカスタマイズ可能) |
定量単位 |
売上高(百万米ドル)、販売数量(個数)、価格(米ドル) |
対象セグメント |
製品タイプ別(機器、試薬、消耗品)、検査方法別(処方箋に基づく検査およびOTC検査)、技術別(イオン交換HPCL、酵素アッセイ、アフィニティー結合クロマトグラフィー、比濁阻害免疫アッセイなど)、エンドユーザー別(研究所、病院、診療所、在宅ケア、外来センター、薬局/ドラッグストアなど)、流通チャネル別(第三者流通、直接販売および小売販売)、国別(サウジアラビア、エジプト、トルコ) |
対象国 |
サウジアラビア、エジプト、トルコ |
対象となる市場プレーヤー |
サウジアラビア、エジプト、トルコの HbA1c 検査市場で活動している主要企業には、Siemens Healthcare GmbH、A. Menarini Diagnostics srl、ARKRAY, Inc.、Trinity Biotech、Thermo Fisher Scientific Inc.、Abbott、Wondfo、F. Hoffmann-La Roche Ltd、Ortho Clinical Diagnostics、DxGen Corp. などがあります。 |
サウジアラビア、トルコ、エジプトの HbA1c 検査市場の定義
A blood test called a haemoglobin A1C (HbA1C) test reveals your average blood sugar (glucose) level over the previous two to three months. Your blood contains glucose; a form of sugar that is obtained from the food you eat. Glucose provides energy to your cells. The hormone insulin aids in the uptake of glucose by your cells. If you have diabetes, your body either produces insufficient insulin, or your cells don't properly utilize it. Because of the inability of glucose to enter your cells, your blood sugar levels rise.
Diabetes is a global endemic with rapidly increasing prevalence in developing and developed countries. Glycated hemoglobin (HbA1c) as a possible substitute to fasting blood glucose for diagnosis of diabetes HbA1c is an important indicator of long-term glycemic control with the ability to reflect the cumulative glycemic history of the preceding two to three months. HbA1c provides a reliable measure of chronic hyperglycemia and correlates well with the risk of long-term diabetes complications. Elevated HbA1c has also been regarded as an independent risk factor for coronary heart disease and stroke in subjects with or without diabetes. The valuable information provided by a single HbA1c test has rendered it a reliable biomarker for the diagnosis and prognosis of diabetes. However, the High cost of HBA1C testing devices and kits and standards for the approval and commercialization of products is expected to restrain the market growth.
Saudi Arabia, Turkey, and Egypt HbA1c Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing prevalence of diabetes worldwide
The number of young people under age 20 with diabetes is likely to increase more rapidly in future. There are also various studies for the rise in type 2 diabetes including the increasing prevalence of childhood obesity. The presence of diabetes in people of childbearing age might is much important because maternal diabetes increases risk of diabetes in children.
The rising demand for hba1c testing with improved accuracy and less time constraint are pushing the key players for strategic initiatives. As people with diabetes are at higher risk for heart disease or a stroke, diabetes complications and premature death than those who do not have diabetes
- Growing awareness about the importance of glycemic control
Poor glycemic control is characterized by the chronically high levels of blood sugar and glycated hemoglobin such as diabetic patients especially those treated with insulin are at risk for developing hypoglycemia. Some studies suggest that an increase in non-exercise physical activity is effective in reducing postprandial hyperglycemia and improving glycemic control
Various studies revealed that many diabetic patients had inadequate and poor glycemic control levels. And this was associated with older age, longer duration of DM, insulin therapy, poor diet compliance, and failure to set control goals. This requires focusing on the identified factors and tailored management mechanisms to maintain good glycemic control. So, people are getting more concerned over this factor and preparing themselves to control their level of glycemic
However, a low level of knowledge of diabetes may act as a predictor of poor glycemic control but not as a medication adherence.
Restraint
- High cost OF hba1c testing devices and kits
The devices and kits cost plays important role in the hba1c testing market. As the development process for these devices and kits is quite expensive and take a long time to pass through R&D, regulatory and various other compliances. These devices and kits requires a start with a high-level understanding of the process from a design to production to the way the product will be manufactured as a single error in any stage can cause disruption in the whole production.
For Instance,
- In December 2020, as per NCBI article, in Saudi Arabia the health expenditure for people diagnosed with diabetes compared to expenditure in the absence of diabetes is ten times higher
However, these hba1c devices and kits demand an effective investment for successful operations along with a project risk management plan.
Opportunity
-
Increasing adoption of hba1c testing in emerging markets
The regulations and doctor recommendation plays important role in increasing adoption of hba1c testing. The stringent rules and regulations are necessary for government approval to ensure the security and safety of the humans and environment. As hba1c is one of the commonly used test to diagnose prediabetes and diabetes and is also considered the main test to help you and your health care team manage your diabetes. Pre-diabetics or people having borderline diabetes, are also advised by doctors to get tested to check how stable their blood sugar levels are. In general doctor’s opinion people having diabetes and pre-diabetes should get their HbA1c tested every 3 months.
Challenge
- Challenges in interpreting hba1c results in patients with anemia or kidney disease
The underlying challenges associated with the predictive ability of HbA1c persist in chronic kidney disease environments. Excess fluid and waste from blood remain in the body and may cause other health problems such as heart disease and stroke.
However, HbA1c levels may be falsely elevated or decreased in chronic kidney disease because a uremic environment shortens the red blood cell lifespan. Several studies have provided the speculation that in populations with a high prevalence of inflammation and malnutrition, such as chronic kidney disease HbA1c levels could be less predictive of clinical outcomes.
For instance-
- In February 2022 – As per ncbi article study conducted by researchers in the gulf cooperation council countries stated that HbA1c level of 7% to 8% may be the most favorable for the best outcomes for diabetes mellitus patients in advanced chronic kidney disease
However, mild-to-moderate anemia and chronic kidney disease may not affect the relationship between glycated hemoglobin and blood glucose level.
Recent Developments
- In March 2020, PTS Diagnostics recently announced that they would launch A1CNow+ Controls for the A1CNow®+ Test System. A1CNow+ Controls are initially accessible in the US, EU, and UK. They can be kept frozen for up to three years, chilled for eight months, or at room temperature for seven days. The solution has two levels, each in a dropper-style vial, and may be effectively used in minutes. Its goal is to ensure accurate A1C findings.
- In March 2023, Abbott announced a definitive agreement with Cardiovascular Systems, Inc. (CSI), a manufacturer of medical devices with a cutting-edge atherectomy system used to treat peripheral and coronary artery disease, under which Abbott would purchase CSI. Abbott's market-leading vascular device lineup will gain access to fresh, complementary innovations thanks to the purchase of CSI. This has caused the business to grow for the corporation.
Saudi Arabia, Turkey, and Egypt HbA1c Testing Market Scope
Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into five notable segments such as product type, mode of testing, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- Instruments
- Reagents And Consumables
On the basis of product type, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into instruments, reagents, and consumables.
BY MODE OF TESTING
- Prescription Based Testing
- OTC Testing
On the basis of mode of testing, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into prescription based testing and OTC testing.
BY TECHNOLOGY
- Turbidimetric Inhibition Immunoassay
- Ion-Exchange HPLC
- Affinity Binding Chromatography
- Enzymatic Assay
- Others
On the basis of technology, the Saudi Arabia, Turkey, and Egypt HbA1c testing market is segmented into ion exchange HPCL, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others.
BY END USER
- Laboratories
- Hospitals
- Clinics
- Homecare
- Ambulatory Centers
- Pharmacies/Drug Stores
- Others
エンドユーザーに基づいて、サウジアラビア、トルコ、エジプトの HbA1c 検査市場は、研究所、病院、診療所、在宅ケア、外来センター、薬局/ドラッグストア、その他に分類されます。
流通チャネル別
- 直接販売
- 第三者配信
- 小売販売
流通チャネルに基づいて、サウジアラビア、トルコ、エジプトの HbA1c 検査市場は、サードパーティ流通、直接販売、小売販売に分類されます。
サウジアラビア、トルコ、エジプトの HbA1c 検査市場の地域分析/洞察
サウジアラビア、トルコ、エジプトの HbA1c 検査市場は、製品タイプ、検査モード、テクノロジー、エンドユーザー、流通チャネルなど、4 つの主要なセグメントに分類されています。
この市場レポートで取り上げられている国は、サウジアラビア、トルコ、エジプトです。人口における糖尿病および糖尿病前症の罹患率が上昇しているため、サウジアラビア、トルコ、エジプトの HbA1c 検査市場ではトルコが優位に立つと予想されています。
レポートの州セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境とサウジアラビア、トルコ、エジプトの HbA1c 検査市場シェア分析
サウジアラビア、トルコ、エジプトの HbA1c 検査市場の競争環境は、競合他社によって詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、および技術ライフライン曲線があります。提供されている上記のデータ ポイントは、サウジアラビア、トルコ、エジプトの HbA1c 検査市場への会社の重点にのみ関連しています。
サウジアラビア、トルコ、エジプトの HbA1c 検査市場で活動している主要企業には、Siemens Healthcare GmbH、A. Menarini Diagnostics srl、ARKRAY, Inc.、Trinity Biotech、Thermo Fisher Scientific Inc.、Abbott、Wondfo、F. Hoffmann-La Roche Ltd、Ortho Clinical Diagnostics、DxGen Corp. などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, INDUSTRY INSIGHTS
6 REGULATORY FRAMEWORK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF DIABETES WORLDWIDE
7.1.2 GROWING AWARENESS ABOUT THE IMPORTANCE OF GLYCEMIC CONTROL
7.1.3 GROWING DEMAND FOR POINT-OF-CARE TESTING DEVICES
7.2 RESTRAINTS
7.2.1 HIGH COST OF HBA1C TESTING DEVICES AND KITS
7.2.2 INADEQUATE HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 INCREASING ADOPTION OF HBA1C TESTING IN EMERGING MARKETS
7.3.2 INTEGRATION OF HBA1C TESTING WITH ELECTRONIC MEDICAL RECORDS AND TELEMEDICINE
7.4 CHALLENGES
7.4.1 INACCURATE RESULTS DUE TO INTERFERENCE FROM VARIOUS HEMOGLOBIN VARIANTS
7.4.2 CHALLENGES IN INTERPRETING HBA1C RESULTS IN PATIENTS WITH ANEMIA OR KIDNEY DISEASE
8 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 POINT OF CARE DEVICES
8.2.2 FACILITY BASED PLATFORM
8.3 REAGENTS AND CONSUMABLES
9 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY MODE OF TESTING
9.1 OVERVIEW
9.2 PRESCRIPTION BASED TESTING
9.3 OTC TESTING
10 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 TURBIDIMETRIC INHIBITION IMMUNOASSAY
10.3 ION-EXCHANGE HPLC
10.4 AFFINITY BINDING CHROMATOGRAPHY
10.5 ENZYMATIC ASSAY
10.6 OTHERS
11 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 LABORATORIES
11.3 HOSPITALS
11.4 CLINICS
11.5 HOMECARE
11.6 AMBULATORY CENTRES
11.7 PHARMACIES/ DRUG STORES
11.8 OTHERS
12 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT SALES
12.3 THIRD PARTY DISTRIBUTION
12.4 RETAIL SALES
12.4.1 HOSPITAL PHARMACY
12.4.2 ONLINE PHARMACY
12.4.3 OTHERS
13 SAUDI ARABIA, TURKEY AND EGYPT HBA1C TESTING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
13.2 COMPANY SHARE ANALYSIS: TURKEY
13.3 COMPANY SHARE ANALYSIS: EGYPT
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F.HOFFMANN- LA ROCHE LTD.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 SIEMENS HEALTHINEERS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 ORTHO CLINICAL DIAGNOSTICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 ARKRAY, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENTS
15.5 THERMO FISCHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIO RAD LABORATORIES, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 DIASYS DIAGNOSTIC SYSTEMS GMBH
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 DXGEN CORP.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 A. MENARINNI DIAGNOSTICS S.R.L
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 PTS DIAGNOSTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 RADIOMETER MEDICAL APS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 TRINITY BIOTECH
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 VITROSENS BIOTECHNOLOGY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 WONDFO
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
図表一覧
FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE SAUDI ARABIA HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 12 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE TURKEY HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 13 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EGYPT HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 14 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 15 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 16 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF SAUDI ARABIA, TURKEY & EGYPT HBA1C TESTING MARKET
FIGURE 18 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 23 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 24 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 25 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 26 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 27 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 28 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 29 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 30 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 31 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 32 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 33 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 34 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 35 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 36 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 37 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 38 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 39 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 40 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 41 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 42 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 43 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 44 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 45 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 46 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 47 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 48 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 49 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 50 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 51 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 52 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 53 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 54 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 55 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 56 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 57 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 TURKEY HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 59 TURKEY HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 60 TURKEY HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 61 TURKEY HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 EGYPT HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 63 EGYPT HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 64 EGYPT HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 65 EGYPT HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 66 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 67 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 68 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 69 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 71 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 72 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 73 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 74 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 75 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 76 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 77 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 78 SAUDI ARABIA HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 79 TURKEY HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 80 EGYPT HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。